- Pooled analysis of 6 clinical trials indicates that tofacitinib treatment is well tolerated and has a similar benefit-risk profile as other systemic treatments in patients with moderate to severe chronic plaque psoriasis.
Why this matters
- Tofacitinib appears to be a safe and effective alternative for patients with moderate to severe psoriasis, particularly those who require treatment switching.
- Greater proportions of patients receiving tofacitinib 5 or 10 mg twice daily vs placebo achieved Physician’s Global Assessment (PGA) "clear" or "almost clear" (44.0%, 59.1%, and 10.0%, respectively; P<.0001 and improvement in psoriasis area severity index respectively p at week>
- Adverse events (AEs) were reported in 54.0% of patients who received tofacitinib 5 mg twice daily, 58.9% of patients who received tofacitinib 10 mg twice daily, and 50.4% of patients who received placebo.
- 2.6%, 3.1%, and 4.9%, respectively, discontinued because of AEs.
- In tofacitinib-treated patients, the most frequently observed serious infections were pneumonia (0.4%), herpes zoster (0.2%), and appendicitis (0.2%).
- Data from 1 phase 2 trial, 4 phase 3 trials, and 1 long-term extension study were pooled to analyze the efficacy and safety of tofacitinib.
- Funding: Pfizer Inc.
- Clinical trial population may not match real-world settings.